The effects of mannuronic acid on IL‐1β, IL‐17A, STAT1 and STAT3 gene expression and TLR2 and TLR4 molecules in multiple sclerosis

2021 ◽  
Author(s):  
Soheil Najafi ◽  
Payam Saadat ◽  
Nahid Beladi Moghadam ◽  
Ali Manoucherinia ◽  
Zahra Aghazadeh ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Mannuronic Acid

The Relation between Age, Gender and Apoptosis Regulator FasL Gene Expression in Multiple Sclerosis Patients

2016 ◽  
Vol 5 (3) ◽  
Author(s):  
A. Faraz ◽  
R. Yari ◽  
M. Taheri ◽  
M. Omrani ◽  
M. Saberi ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Fasl Gene ◽  
Multiple Sclerosis Patients

Assessment of biochemical determinants in Multiple Sclerosis patients following the oral administration of β-D-Mannuronic acid [M2000]

2020 ◽  
Vol 17 ◽  
Author(s):  
Mohamad Reza Nikouei Moghaddam ◽  
Monireh Movahedi ◽  
Maryam Bananej ◽  
Soheil Najafi ◽  
Nahid Beladi Moghadam ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Uric Acid ◽  
Vitamin D3 ◽  
Chronic Inflammatory Disease ◽  
Toxic Effects ◽  
Control Group ◽  
Therapeutic Effects ◽  
Mannuronic Acid ◽  
Anti Inflammatory ◽  
Multiple Sclerosis Patients

Background: Multiple sclerosis is an autoimmune chronic inflammatory disease of the central nervous system that can lead to some serious disabilities. Despite using various immunomodulatory and anti-inflammatory drugs that have therapeutic effects, they cannot reduce its progression completely, and have some unwanted side effects too. The immunomodulatory and anti-inflammatory effects of the β-D-Mannuronic acid [M2000] have been proven in several surveys, and the present research was designed to determine its toxicity and therapeutic effects in MS patients. Methods: This study was performed on 15 MS patients who took 25 mg/kg/day the oral form of the β-D-Mannuronic acid for six months, and 15 healthy people as a control group. Serum levels of Urea, Creatinine, GGT, Vitamin D3, Uric acid, and Anti-Phospholipids were compared to evaluate the therapeutic and possible toxic effects of this drug after this period. Results: Non- toxic effects through the study of Urea, Creatinine, GGT, and non-significant changes in Uric acid and AntiPhospholipids levels, besides a significant rise in Vitamin, D3 levels in the M2000 treated cases were found. Conclusions: Our results suggested that β-D-Mannuronic acid is a safe drug and has no toxicity when administered orally and also has some therapeutic effects in MS patients.

scholarly journals N6-Methyladenosine RNA modification in cerebrospinal fluid as a novel potential diagnostic biomarker for progressive multiple sclerosis

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Fei Ye ◽  
Tianzhu Wang ◽  
Xiaoxin Wu ◽  
Jie Liang ◽  
Jiaoxing Li ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Clustering Analysis ◽  
Roc Curves ◽  
Progressive Multiple Sclerosis ◽  
Rna Modification ◽  
Diagnostic Model ◽  
Consensus Clustering ◽  
Rna Methylation ◽  
M6a Rna Methylation

Abstract Background Progressive multiple sclerosis (PMS) is an uncommon and severe subtype of MS that worsens gradually and leads to irreversible disabilities in young adults. Currently, there are no applicable or reliable biomarkers to distinguish PMS from relapsing–remitting multiple sclerosis (RRMS). Previous studies have demonstrated that dysfunction of N6-methyladenosine (m6A) RNA modification is relevant to many neurological disorders. Thus, the aim of this study was to explore the diagnostic biomarkers for PMS based on m6A regulatory genes in the cerebrospinal fluid (CSF). Methods Gene expression matrices were downloaded from the ArrayExpress database. Then, we identified differentially expressed m6A regulatory genes between MS and non-MS patients. MS clusters were identified by consensus clustering analysis. Next, we analyzed the correlation between clusters and clinical characteristics. The random forest (RF) algorithm was applied to select key m6A-related genes. The support vector machine (SVM) was then used to construct a diagnostic gene signature. Receiver operating characteristic (ROC) curves were plotted to evaluate the accuracy of the diagnostic model. In addition, CSF samples from MS and non-MS patients were collected and used for external validation, as evaluated by an m6A RNA Methylation Quantification Kit and by real-time quantitative polymerase chain reaction. Results The 13 central m6A RNA methylation regulators were all upregulated in MS patients when compared with non-MS patients. Consensus clustering analysis identified two clusters, both of which were significantly associated with MS subtypes. Next, we divided 61 MS patients into a training set (n = 41) and a test set (n = 20). The RF algorithm identified eight feature genes, and the SVM method was successfully applied to construct a diagnostic model. ROC curves revealed good performance. Finally, the analysis of 11 CSF samples demonstrated that RRMS samples exhibited significantly higher levels of m6A RNA methylation and higher gene expression levels of m6A-related genes than PMS samples. Conclusions The dynamic modification of m6A RNA methylation is involved in the progression of MS and could potentially represent a novel CSF biomarker for diagnosing MS and distinguishing PMS from RRMS in the early stages of the disease.

Different neuroinflammatory gene expression profiles in highly active and benign multiple sclerosis

2021 ◽  
pp. 577650
Author(s):  
Maria Ivanova ◽  
Anastasiya Voronkova ◽  
Vladimir Sukhorukov ◽  
Maria Zakharova
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Highly Active ◽  
Benign Multiple Sclerosis

TRAIL gene expression analysis in multiple sclerosis patients

2016 ◽  
Vol 24 (1-2) ◽  
pp. 33-38 ◽  
Author(s):  
Mohammad Taheri ◽  
Shirin Nemati ◽  
Abolfazl Movafagh ◽  
Mohammad Saberi ◽  
Reza Mirfakhraie ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Expression Analysis ◽  
Gene Expression Analysis ◽  
Multiple Sclerosis Patients

scholarly journals The multiple sclerosis drug fingolimod (FTY720) stimulates neuronal gene expression, axonal growth and regeneration

2016 ◽  
Vol 279 ◽  
pp. 243-260 ◽  
Author(s):  
Sofia Anastasiadou ◽  
Bernd Knöll
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Axonal Growth ◽  
Neuronal Gene

scholarly journals Gene Expression Profiling of Multiple Sclerosis Pathology Identifies Early Patterns of Demyelination Surrounding Chronic Active Lesions

2017 ◽  
Vol 8 ◽  
Author(s):  
Debbie A. E. Hendrickx ◽  
Jackelien van Scheppingen ◽  
Marlijn van der Poel ◽  
Koen Bossers ◽  
Karianne G. Schuurman ◽  
...  
Keyword(s):  
Gene Expression ◽  
Multiple Sclerosis ◽  
Gene Expression Profiling ◽  
Expression Profiling
Sign in / Sign up

Export Citation Format

Share Document